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Chun-Yi Lu, Yung-Tien Ting, Li-Min Huang*Department of Pediatrics, National Taiwan University Hospital, Taipei, TaiwanReceived 10 February 2014; accepted 17 February 2014We read with great interest the article written by Ho et al1
on breakthrough pneumococcal 19A bacteremia in a child
immunized with 10-valent pneumococcal conjugate vaccine
(PCV10). We believe that breakthrough infections are
inevitable because the protective efficacy of a given vac-
cine is not 100%. We would like to share our experience in
severe breakthrough Streptococcus pneumoniae pneumonia
with empyema after vaccinations with either PCV10 or
PCV13 in Taiwan.
Patient 1 was a previously healthy boy aged 2 years and 9
months, who was transferred to our hospital due to fever
for 6 days and progressive dyspnea for 2 days. He had
received 2 þ 1 doses of PCV10 at 8 months, 9 months, and
12 months of ages. On admission, he had high fever (rectal
temperature 40C) and tachypnea (respiratory rate 40e60/
min). Chest auscultation revealed crackles and a decreased
breathing sound over the right upper lung field. Chest
radiograph and computed tomography (CT) scan showed
consolidation of the right upper lung fields and moderate
right pleural fluid accumulation (Fig. 1A). The white
blood cell count was 18.7  109/L (neutrophils 89%). The
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space was performed with video-assisted thoracostomy
surgery (VATS). S. pneumoniae serotype 19A was isolated
from the pleural effusion. The minimum inhibitory con-
centration was 4 mg/mL for penicillin. Vancomycin and
cefotaxime were used for 2 weeks, and then he was put on
oral levofloxacin for 1 more week. A follow-up chest
radiograph at 2 weeks after admission showed a septated
cavitating lesion in the right upper lung field (Fig. 1C).
Over the past few years, we have also encountered
similar clinical presentations in several children aged 2e5
years who had received one dose of PCV13 catch-up
vaccination after the age of 2 years. For example, Patient
2 was a boy aged 4 years and 3 months when he presented
to our hospital with right lower lobe pneumonia and em-
pyema (Fig. 1B and D); S. pneumoniae 19A was detected in
his pleural effusion by polymerase chain reaction. Early
VATS and second-line antibiotics were needed to treat
these patients.
In Taiwan, invasive pneumococcal disease (IPD) is a
reportable disease. In 2012 and 2013, there were 749 IPD
cases and 618 IPD cases reported, respectively. Among IPD
in children aged less than 5 years, 61.4% and 52.7% were
caused by 19A in respective years.2 19A is a prevalent
serotype and causes severe empyema in Taiwan.3 Taiwan
did not have nationwide PCV immunization programs until
2012, when four doses of PCV13 were provided to selected
high-risk groups. Later in 2013, all children aged 2e5 years
were provided with a single dose of PCV13. The program
was further extended to children aged 1 year; two doses ofAssociation. All rights reserved.
Figure 1 Chest radiographs and computed tomography scans of Patient 1 (A,C) and Patient 2 (B,D).
784 C.-Y. Lu et al.PCV13 have been provided to children aged 1 year since
2014.
The efficacy of PCV13 against IPD caused by new sero-
types was based on a putative correlate of protection. Ef-
ficacy studies on PCV13 are not available. Postmarketing
case control studies showed that one or more doses of
PCV13 decreased approximately 70% of invasive pneumo-
coccal 19A infections in the UK.4 By contrast, a cluster
randomized trial of PCV10 done in Finland showed 100%
protective efficacy against 19A.5 However, 19A is rare in
Finland and there was only one 19A case in the control
group. Whether PCV10 provides cross-protection against
19A remains a controversy.
We agree with Ho et al that clinicians should bear in
mind that invasive 19A infections could occur in children
fully immunized with PCV10. We would like to add that
children receiving PCV13, especially those who receive
incomplete or one-dose catch-up vaccinations, are not
totally immune against 19A either. Severe breakthrough
infections may occur.References
1. Ho PL, Chan MY, Chow KH, Chiu SS. Streptococcus pneumoniae
serotype 19A bacteremia in a child fully immunized with 10-
valent pneumococcal conjugate vaccine. J Microbiol Immunol
Infect; 2013. http://dx.doi.org/10.1016/j.jmii.2013.09.008.
2. Department of Disease Control, Ministry of Health and Welfare,
Taiwan. Invasive pneumococcal diseases (in Chinese)
2012e2013. Available at: http://nidss.cdc.gov.tw/ [accessed
04.01.14].
3. Shen CF, Wang SM, Lee KH, Ho TS, Liu CC. Childhood invasive
pneumococcal disease caused by non-7-valent pneumococcal
vaccine (PCV7) serotypes under partial immunization in
Taiwan. J Formos Med Assoc 2013;112:561e8.
4. Miller E, Andrews NJ, Waight PA, Slack MP, George RC. Effec-
tiveness of the new serotypes in the 13-valent pneumococcal
conjugate vaccine. Vaccine 2011;29:9127e31.
5. Palmu AA, Jokinen J, Borys D, Nieminen H, Ruokokoski E,
Siira L, et al. Effectiveness of the ten-valent pneumococcal
Haemophilus influenzae protein D conjugate vaccine (PHiD-
CV10) against invasive pneumococcal disease: a cluster rand-
omised trial. Lancet 2013;381:214e22.
